Provectus Pharmaceuticals Inc. Begins Phase 2 Clinical Trial for Atopic Dermatitis

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) has begun Phase 2 clinical testing of PH-10, the company's topical drug for dermatology, for the treatment of atopic dermatitis, a chronic skin condition that includes some forms of eczema. The study is designed to evaluate efficacy of PH-10 in a total of twenty subjects with mild to severe forms of the disease.

Back to news